Page 2 - Glenmark Pharmaceuticals Ltd News

Stocks to Watch today, Nov 17: Maruti Suzuki, Ola Electric, Marico, Lupin

Stocks to Watch Today, November 17, 2025: Marico, Glenmark Pharma, FirstCry, Siemens, Dish TV, Alembic Pharma, Cyient, and Websol Energy System are among the top stocks to remain in focus today

Glenmark Pharmaceuticals Q2 results: Profit jumps 72% to ₹610.43 cr

Glenmark Pharmaceuticals Ltd on Friday reported a 72.2 per cent jump in consolidated profit after tax at Rs 610.43 crore in the second quarter ended September 2025 on the back of its licensing deal with AbbVie for investigational asset 'ISB 2001'. The company had posted a consolidated profit after tax (PAT) of Rs 354.49 crore in the corresponding period last fiscal, Glenmark Pharmaceuticals Ltd said in a regulatory filing. Consolidated total revenue from operations was at Rs 6,046.87 crore as against Rs 3,433.8 crore in the same period a year ago, it added. Total expenses in the quarter under review were at Rs 3,894.98 crore as against Rs 3,000.64 crore in the same period last fiscal, the company said. "Q2FY26 reflects the steady progress we are making in strengthening Glenmark's scientific and strategic foundation. The AbbVie partnership for ISB 2001, along with the income recognised this quarter, is a significant validation of our scientific strength and enables us to advance the

Stocks to Watch today: Vi, Bajaj Finance, Emami, Ather, Britannia, Glenmark

Stocks to Watch today: Vodafone Idea, Bajaj Finance, Emami, Ather Energy, Britannia Industries and Glenmark Pharma are among the stocks to watch today, November 11, 2025

Glenmark gets China approval for Ryaltris nasal spray for allergies

Glenmark's Ryaltris nasal spray, already approved in the US, EU and other markets, has now secured China's NMPA approval, strengthening its global respiratory portfolio

Glenmark's Ryaltris nasal spray gets China approval for allergic rhinitis

Glenmark Pharmaceuticals Ltd on Monday said its arm Glenmark Specialty SA has received approval from China's National Medical Products Administration for the nasal spray RYALTRIS used to treat allergic rhinitis. The National Medical Products Administration (NMPA) of China has approved RYALTRIS Compound Nasal Spray (GSP 301 NS) for the treatment of allergic rhinitis (AR) in adults and children -- specifically for treatment of moderate to severe seasonal AR in adults and pediatric patients 6 years of age and older, and moderate to severe perennial AR in adults and pediatric patients 12 years of age and older, the company said in a statement. The approval granted with zero supplementation requests is an important milestone in Glenmark's respiratory pipeline and reflects continued progress in advancing innovative and differentiated therapies for patients with chronic conditions, it added. "The approval of RYALTRIS in China is a significant step in expanding our specialty respiratory ...